Filter Results:
(4,896)
Show Results For
- All HBS Web
(4,896)
- People (17)
- News (1,945)
- Research (2,371)
- Events (2)
- Multimedia (221)
- Faculty Publications (1,859)
Show Results For
- All HBS Web
(4,896)
- People (17)
- News (1,945)
- Research (2,371)
- Events (2)
- Multimedia (221)
- Faculty Publications (1,859)
- 2018
- Chapter
Competing Interests
By: Joel Goh
Book Abstract: The editors, aided by a team of internationally acclaimed experts, have curated this timely volume to help newcomers and seasoned researchers alike to rapidly comprehend a diverse set of thrusts and tools in this rapidly growing cross-disciplinary field.... View Details
Goh, Joel. "Competing Interests." Chap. 4 in Handbook of Healthcare Analytics: Theoretical Minimum for Conducting 21st Century Research on Healthcare Operations, edited by Tinglong Dai and Sridhar Tayur, 51–78. John Wiley & Sons, 2018.
- Web
MS/MBA Biotechnology: Life Sciences | MBA
and life science community include, the Harvard Business School (HBS) Health Care Initiative (HCI), HBS Blavatnik Fellowship in Life Science Entrepreneurship, the Harvard Biotech Club, the HBS View Details
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation ＆ Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Health Industry; Health Industry; Health Industry; Health Industry; Health Industry; United States
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
- May 2014 (Revised March 2017)
- Case
Unilever's Lifebuoy in India: Implementing the Sustainability Plan
Unilever's new Global Brand VP must not only revitalize Lifebuoy soap's sagging market performance, but simultaneously impact the health of one billion people worldwide. The latter challenge comes from Unilever's new CEO who has introduced the Unilever Sustainable... View Details
Keywords: Multinational Management; Corporate Social Responsibility; Strategy Implementation; Marketing Strategy; Mission And Purpose; Change Management; International Business; Global; Fast-moving Consumer Goods; Soap; Corporate Social Responsibility and Impact; Health Care and Treatment; Environmental Sustainability; Global Strategy; Developing Countries and Economies; Beauty and Cosmetics Industry; Health Industry; India
Bartlett, Christopher A. "Unilever's Lifebuoy in India: Implementing the Sustainability Plan." Harvard Business School Case 914-417, May 2014. (Revised March 2017.)
- 07 Nov 2014
- Working Paper Summaries
Do Experts or Collective Intelligence Write with More Bias? Evidence from Encyclopædia Britannica and Wikipedia
- February 2010 (Revised March 2012)
- Case
U.S. Healthcare Reform: International Perspectives
By: Arthur A. Daemmrich and Elia Cameron
The national economic implications of rising healthcare costs were poorly understood, even as the United States, Germany, and the United Kingdom instituted reforms in early 2010. Presenting opportunities for cross-national policy learning, this case describes the... View Details
Keywords: Macroeconomics; Insurance; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Laws and Statutes; Business and Government Relations; Health Industry; Health Industry; Germany; United Kingdom; United States
Daemmrich, Arthur A., and Elia Cameron. "U.S. Healthcare Reform: International Perspectives." Harvard Business School Case 710-040, February 2010. (Revised March 2012.)
- January 2011 (Revised January 2012)
- Supplement
The Case of the Unidentified Healthcare Companies2010 (CW)
By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- September 2007
- Case
Collaborating to Improve
By: Richard M.J. Bohmer and Ingrid M. Nembhard
Madison Memorial Hospital is deciding between a variety of quality improvement strategies. Highlights quality improvement collaborative—organized programs popularized by the Institute for Healthcare Improvement in which teams from multiple institutions work together to... View Details
Keywords: Health Care and Treatment; Service Delivery; Performance Improvement; Quality; Groups and Teams; Cooperation; Integration; Health Industry
Bohmer, Richard M.J., and Ingrid M. Nembhard. "Collaborating to Improve." Harvard Business School Case 608-054, September 2007.
- 10 Jul 2020
- News
Sutter Health’s Request to Delay $575 Million Settlement Is Denied
- 09 Jan 2015
- News
Report: Don't let integration cause physician micromanagement
- January 2011 (Revised April 2014)
- Case
Uptake of Malaria Rapid Diagnostic Tests
By: Nava Ashraf, Natalie Kindred and Richard Sedlmayr
This case describes barriers to adoption of malaria rapid diagnostic tests in Zambia and highlights the importance of understanding end users in promoting product adoption. Rapid diagnostic tests (RDTs) are simple, easy-to-use tools that provide a relatively reliable,... View Details
Keywords: Developing Countries and Economies; Health Pandemics; Technology; Health Care and Treatment; Policy; Behavior; Prejudice and Bias; Health Industry; Zambia
Ashraf, Nava, Natalie Kindred, and Richard Sedlmayr. "Uptake of Malaria Rapid Diagnostic Tests." Harvard Business School Case 911-007, January 2011. (Revised April 2014.) (Request a courtesy copy.)
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- Web
VBHCD Intensive Seminars - Institute For Strategy And Competitiveness
HBS ISC Health Care Health Care Value-Based Health Care View Details
- April 1990 (Revised January 1993)
- Case
Ad Council's AIDS Campaign (A): Advertising Strategy
By: V. Kasturi Rangan and Janet Montgomery
Ad Council wished to run an educational campaign aimed at preventing the spread of AIDS. They were challenged to find acceptable ways to address this very sensitive subject matter--ways that the media and the public would approve. One of the big challenges was to make... View Details
Keywords: Advertising; Goals and Objectives; Social Marketing; Corporate Social Responsibility and Impact; Success; Problems and Challenges; Social Issues; Health Industry
Rangan, V. Kasturi, and Janet Montgomery. "Ad Council's AIDS Campaign (A): Advertising Strategy." Harvard Business School Case 590-105, April 1990. (Revised January 1993.)
- December 1998 (Revised September 1999)
- Case
Novartis: Betting on Life Sciences
By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
- 02 Sep 2020
- News
How to Launch a New Biosciences Product: Start Small or Dive in?
- 05 Sep 2017
- News
Bargaining With Cancer Patients About Treatment
- September 2014
- Article
Defining the Value of Proton Therapy Using Time-Driven Activity-Based Costing
By: N.G. Thaker, A.B. Guzman, Thomas W. Feeley, T.M. Jones, J.R. Incalcaterra, C. Kolom, S.J. Frank, L.S. Tatum, Ronald S. Walters, Scott B. Cantor, D.I. Rosenthal, A.S. Garden, G.B. Gunn, C.D. Fuller and M.B. Palmer
Technological innovations in radiation therapy (RT) have rapidly improved the quality of care for patients with head and neck cancer. Intensity-modulated proton therapy (MPT) holds promise of further improving outcomes compared with the current photon-based technique... View Details
Keywords: Time-Driven Activity-Based Costing; Health Care and Treatment; Technological Innovation; Activity Based Costing and Management
Thaker, N.G., A.B. Guzman, Thomas W. Feeley, T.M. Jones, J.R. Incalcaterra, C. Kolom, S.J. Frank, L.S. Tatum, Ronald S. Walters, Scott B. Cantor, D.I. Rosenthal, A.S. Garden, G.B. Gunn, C.D. Fuller, and M.B. Palmer. "Defining the Value of Proton Therapy Using Time-Driven Activity-Based Costing." Oncology Payers, no. 1 (September 2014): 22–28.
- 02 Mar 2023
- Blog Post
Women, Work, and the "M" Word
I’m the eldest of three daughters in a medical family. With a urogynecologist and primary care doctor as parents, I grew up thinking it was normal to talk about all topics of women’s View Details